Cough associated with the new coronavirus infection (COVID-19): rational approaches to pharmacotherapy-Reference-Cited by-同舟云学术

Cough associated with the new coronavirus infection (COVID-19): rational approaches to pharmacotherapy

Published:2022-04-30 Issue:2 Volume:32 Page:232-238
ISSN:2541-9617
Container-title:PULMONOLOGIYA
language:
Short-container-title:Pulʹmonologiâ (Mosk.)

Author:

Okovityi S. V.¹^ORCID,Sukhanov D. S.²^ORCID,Zaicev A. A.³^ORCID

Affiliation:

1. Saint-Petersburg State Chemical and Pharmaceutical University, Healthcare Ministry of the Russian Federation

2. Saint-Petersburg State Budgetary Healthcare Institution “Tuberculosis Dispensary No.12”

3. Main Military Clinical Hospital named after academician N.N.Burdenko, Ministry of Defense of the Russian Federation

Abstract

Cough is one of the most frequent symptoms of the new coronavirus infection (COVID-19). It reduces the quality of life and contributes to the development of life-threatening conditions.Aim. This article analyzes modern approaches to the pharmacotherapy of cough in patients with the new coronavirus infection from the standpoint of pathogenetic justification of the use of drugs. The main mechanisms of cough development in COVID-19 presented in the literature are considered. The cough is associated with virus-induced damage to the epithelium and subsequent release of biologically active substances that irritate the afferent endings of the vagus nerve. Approaches to cough management in COVID-19 with the possible use of antitussive (central and peripheral action) and mucoactive drugs (expectorants, mucokinetics, mucolytics, mucoregulators) are addressed.Conclusion. Based on the literature data and pathogenesis, antitussive drugs play a crucial role in the treatment of cough in COVID-19.

Publisher

Scientific and Practical Reviewed Journal Pulmonology

Subject

Pulmonary and Respiratory Medicine

Reference53 articles.

1. Zaytsev A.A., Chernov S.A., Kryukov E.V. et al. [Practical experience of managing patients with new coronavirus infection COVID-19 in hospital (preliminary results and guidelines)]. Lechashchiy Vrach. 2020; (6): 74–79. DOI: 10.26295/OS.2020.41.94.014 (in Russian).

2. National Institute for Health and Care Excellence (NICE) in collaboration with NHS England and NHS Improvement [corporate author]. Managing COVID-19 symptoms (including at the end of life) in the community: summary of NICE guidelines. BMJ. 2020; 369: m1461. DOI: 10.1136/bmj.m1461.

3. Lovato A., Filippis C. Clinical presentation of COVID-19: a systematic review focusing on upper airway symptoms. Ear Nose Throat J. 2020; 99 (9): 569–576. DOI: 10.1177/0145561320920762.

4. Zaytsev A.A., Okovityy S.V., Miroshnichenko N.A., Kryukov E.V. [Cough: Guidelines for physicians]. Moscow: Burdenko General Clinical Hospital; 2021. Available at: https://www.researchgate.net/publication/354162540_Kasel_Metodiceskie_rekomendacii_dla_vracej_Cough_Guidelines_for_physicians (in Russian).

5. Yong S.J. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect. Dis. (Lond.). 2021; 53 (10): 737–754. DOI: 10.1080/23744235.2021.1924397.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Results of an open observational multicenter study of the effectiveness and tolerability of levodropropizine in comparison with standard antitussive therapy (real practice) in the treatment of patients with COVID-19;PULMONOLOGIYA;2022-08-16